Use of circulating tumor DNA (ctDNA) to complement tumor tissue homologous recombination repair (HRR) gene alteration testing in TALAPRO-2, a phase 3 study of talazoparib (TALA) plus enzalutamide (ENZA) versus placebo (PBO) plus ENZA as first-line (1L) treatment in patients (pts) with metastatic castration-resistant prostate cancer (mCRPC). Meeting Abstract

cited authors

  • Azad, Arun; Fizazi, Karim; Matsubara, Nobuaki; Fong, Peter C. C.; Carles, Joan; Shore, Neal D.; De Giorgi, Ugo; Jones, Robert J.; Karsh, Lawrence Ivan; Joung, Jae Young; Fay, Andre P.; Liu, Glenn; Yip, Steven M.; Zschaebitz, Stefanie; Hopkins, Julia F.; Di Santo, Nicola; Lin, Xun; Mata, Marielena; Laird, Douglas; Agarwal, Neeraj

authors

Publication Date

  • June 1, 2023

webpage

published in

category

volume

  • 41

issue

  • 16_SUPPL